Selecting Target Antigens for Cancer Vaccine Development DOI Creative Commons
Luigi Buonaguro, Maria Tagliamonte

Vaccines, Journal Year: 2020, Volume and Issue: 8(4), P. 615 - 615

Published: Oct. 17, 2020

One of the principal goals cancer immunotherapy is development efficient therapeutic vaccines that are able to elicit an effector as well memory T cell response specific tumor antigens. In recent years, attention has been focused on personalization vaccines. However, efficacy still disappointing despite large number vaccine strategies targeting different tumors have evaluated in years. While preclinical data frequently shown encouraging results, clinical trials not provided satisfactory date. The main reason for such failures complexity identifying target antigens should be unique or overexpressed only by cells compared normal cells. Most included non-mutated self-antigens, eliciting mainly with low-affinity receptors (TCR) unable mediate effective anti-tumor response. this review, employed years described, along potential new classes human endogenous retroviral elements (HERVs), unconventional antigens, and/or heteroclitic peptides.

Language: Английский

Immune checkpoint therapy—current perspectives and future directions DOI
Padmanee Sharma, Sangeeta Goswami,

Deblina Raychaudhuri

et al.

Cell, Journal Year: 2023, Volume and Issue: 186(8), P. 1652 - 1669

Published: April 1, 2023

Language: Английский

Citations

488
Neoantigens: promising targets for cancer therapy DOI Creative Commons
Na Xie, Guobo Shen, Wei Gao

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Jan. 6, 2023

Abstract Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by cells as a result various tumor-specific alterations, such genomic mutation, dysregulated RNA splicing, disordered post-translational modification, integrated viral open reading frames. recognized non-self trigger an immune response that is not subject to central peripheral tolerance. The quick identification prediction neoantigens been made possible advanced next-generation sequencing bioinformatic technologies. Compared tumor-associated antigens, highly immunogenic provide emerging targets personalized serve prospective predictors survival prognosis checkpoint blockade responses. therapies will be aided understanding mechanism underlying neoantigen-induced anti-tumor streamlining process neoantigen-based immunotherapies. This review provides overview on characterization outlines clinical applications immunotherapeutic strategies based neoantigens. We also explore their current status, inherent challenges, translation potential.

Language: Английский

Citations

483
RNA sequencing: new technologies and applications in cancer research DOI Creative Commons

Mingye Hong,

Shuang Tao, Ling Zhang

et al.

Journal of Hematology & Oncology, Journal Year: 2020, Volume and Issue: 13(1)

Published: Dec. 1, 2020

Abstract Over the past few decades, RNA sequencing has significantly progressed, becoming a paramount approach for transcriptome profiling. The revolution from bulk to single-molecular, single-cell and spatial approaches enabled increasingly accurate, individual cell resolution incorporated with information. Cancer, major malignant heterogeneous lethal disease, remains an enormous challenge in medical research clinical treatment. As vital tool, been utilized many aspects of cancer therapy, including biomarker discovery characterization heterogeneity evolution, drug resistance, immune microenvironment immunotherapy, neoantigens so on. In this review, latest studies on technology their applications are summarized, future challenges opportunities discussed.

Language: Английский

Citations

423
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors DOI Creative Commons
Rilan Bai, Zheng Lv, Dongsheng Xu

et al.

Biomarker Research, Journal Year: 2020, Volume and Issue: 8(1)

Published: Aug. 26, 2020

Abstract Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era anti-tumor therapy, with sustained responses and significant survival advantages observed multiple tumors, most patients do not benefit. Therefore, more attention been paid to identification predictive biomarkers for response ICIs, in-depth comprehensive understanding continuously explored recent years. Predictive markers ICIs efficacy have gradually from expression intermolecular interactions within tumor cells various molecules microenvironment, extended exploration circulating host systemic markers. With high-throughput sequencing microarray technology, variety biomarker strategies deeply achieved process single marker multifactorial synergistic Comprehensive predictive-models developed by integrating different types data based on components tumor-host is direction future research will profound impact field precision immuno-oncology. In this review, we analyze course progress as an adjunctive tool immunotherapy effectively identifying discuss their directions achieving

Language: Английский

Citations

395
The Intriguing History of Cancer Immunotherapy DOI Creative Commons
Paula Dobosz, Tomasz Dzieciątkowski

Frontiers in Immunology, Journal Year: 2019, Volume and Issue: 10

Published: Dec. 17, 2019

Immunotherapy is often perceived as a relatively recent advance. In reality, however, one should be looking for the beginnings of cancer immunotherapy under different names far in Antiquity. The first scientific attempts to modulate patients' immune systems cure can attributed two German physicians, Fehleisen and Busch, who independently noticed significant tumour regression after erysipelas infection. next advances came from William Bradley Coley known today Father Immunotherapy. It was attempted harness system treating bone 1891. His achievements were largely unnoticed over fifty years, several seminal discoveries field Immunology, such existence T cells their crucial role immunity 1967, stepped up research towards today. following paper tracks its until events, including 2018 Nobel Prize award James Allison Tasuku Honjo meticulous work on checkpoint molecules potential therapeutic targets. That has led successful development new inhibitors, CAR T-cells oncolytic viruses pace brings highest hope future treatment.

Language: Английский

Citations

367
Turning cold tumors hot: from molecular mechanisms to clinical applications DOI
Jiahui Zhang, Di Huang, Phei Er Saw

et al.

Trends in Immunology, Journal Year: 2022, Volume and Issue: 43(7), P. 523 - 545

Published: May 25, 2022

Language: Английский

Citations

325
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression DOI Creative Commons
Yi‐Ju Chen, Theodoros I. Roumeliotis,

Ya-Hsuan Chang

et al.

Cell, Journal Year: 2020, Volume and Issue: 182(1), P. 226 - 244.e17

Published: July 1, 2020

Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype this demographically distinct disease, we performed deep comprehensive proteogenomic study on prospectively collected cohort Taiwan, representing stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, phosphoproteomic analysis delineated attributes hallmarks tumor progression. Mutational signature revealed age- gender-related mutagenesis mechanisms, prevalence APOBEC mutational younger females over-representation environmental carcinogen-like signatures older females. A proteomics-informed classification distinguished clinical characteristics stage patients with Furthermore, integrated protein network cellular remodeling underpinning trajectories nominated candidate biomarkers for patient stratification therapeutic intervention. This multi-omic architecture may help develop strategies management never-smoker

Language: Английский

Citations

278
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts DOI Creative Commons
Yuchen Wang, Hao Zhang, Chao Liu

et al.

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: Aug. 17, 2022

Abstract The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the targeted treatment molecules: anti-programmed cell death protein 1/programmed ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on several cancer types achieved satisfying results. However, there are still quite lot patients suffering from severe side effects ineffective outcomes. Although current ICI is far satisfying, series novel molecules with remarkable preclinical clinical benefits being widely investigated, like V-domain Ig suppressor activation (VISTA), which can also be called PD-1 homolog (PD-1H), ectonucleotidases: CD39, CD73, CD38, belong to ribosyl cyclase family, etc. In this review, we systematically summarized discussed these molecules' biological structures, molecular features, corresponding drugs, aiming help in-depth understanding promote practice therapy.

Language: Английский

Citations

176
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade DOI Creative Commons
Carlo Genova, Chiara Dellepiane, Paolo Carrega

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 12

Published: Jan. 7, 2022

In the last decade, treatment of non-small cell lung cancer (NSCLC) has been revolutionized by introduction immune checkpoint inhibitors (ICI) directed against programmed death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA-4). spite these improvements, some patients do not achieve any benefit from ICI, inevitably develop resistance to therapy over time. Tumor microenvironment (TME) might influence response immunotherapy due prominent role in multiple interactions between neoplastic cells system. Studies investigating perspective TME pointed out a complex scenario where tumor angiogenesis, soluble factors, suppressive/regulatory elements composing itself participate growth. this review, we point current state knowledge involving relationship components NSCLC as well their with providing an update on novel predictors currently employed ICI new therapeutic targets investigational agents. first place, increasing evidence suggests that represent promising biomarker sensitivity based presence immune-modulating cells, such Treg, myeloid derived suppressor associated macrophages, which are known induce immunosuppressive environment, poorly responsive ICI. Consequently, clinical studies have designed towards pro-immunogenic subsequently improve activity Currently, mostly approach relies association “classic” targeting PD-1/PD-L1 agents molecules, LAG-3 TIM-3. To date, trials already shown results, while multitude prospective ongoing, results significantly future immunotherapy.

Language: Английский

Citations

163
New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries DOI Creative Commons
Tejeshwar Jain, Prateek Sharma,

Abhi C. Are

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: Feb. 23, 2021

The past decade has witnessed groundbreaking advances in the field of microbiome research. An area where immense implications have been demonstrated is tumor biology. affects initiation and progression through direct effects on cells indirectly manipulation immune system. It can also determine response to cancer therapies predict disease survival. Modulation be harnessed potentiate efficacy immunotherapies decrease their toxicity. In this review, we comprehensively dissect recent evidence regarding interaction anti-tumor machinery outline critical questions which need addressed as further explore dynamic colloquy.

Language: Английский

Citations

132